Nkarta Total Assets 2020-2021 | NKTX

Nkarta total assets from 2020 to 2021. Total assets can be defined as the sum of all assets on a company's balance sheet.
Nkarta Annual Total Assets
(Millions of US $)
2020 $338
2019 $48
Nkarta Quarterly Total Assets
(Millions of US $)
2021-09-30 $292
2021-06-30 $309
2021-03-31 $326
2020-12-31 $338
2020-09-30 $352
2020-06-30 $44
2020-03-31 $0
2019-12-31 $0
2019-09-30 $0
2019-06-30 $0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.346B $0.000B
Nkarta Inc. is a biopharmaceutical company. It develops and commercializes cell therapies for cancer treatment. The company's product candidate includes NKX101 and NKX019, which are in clinical stage. Nkarta Inc. is based in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.036B 8.91
Bio-Rad Laboratories (BIO.B) United States $17.472B 35.46
QIAGEN (QGEN) Netherlands $11.101B 18.80
Biohaven Pharmaceutical Holding (BHVN) United States $7.210B 0.00
Emergent Biosolutions (EBS) United States $2.527B 9.09
Arcus Biosciences (RCUS) United States $2.184B 0.00
Myovant Sciences (MYOV) United Kingdom $1.260B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.080B 0.00
Zymeworks (ZYME) Canada $0.522B 0.00
SQZ Biotechnologies (SQZ) United States $0.201B 0.00
Ambrx Biopharma (AMAM) United States $0.191B 0.00
Enzo Biochem (ENZ) United States $0.154B 19.81